Entering 2021 with a strong reputation following a year of intense pandemic-related research, the biopharma industry is drawing enormous investor interest as financings continue to shoot skyward.
According to an analysis conducted by BioWorld of the 2020 financial reports filed by public biopharmaceutical companies with market caps greater than $1 billion, and excluding big pharma companies, the amount that was invested in research and development (R&D) during the year increased by 23% compared to the same period last year.
NEW DELHI – Significant disruptions to supplies of active pharmaceutical ingredients (APIs) from China caused by the COVID-19 pandemic have led India to fundamentally rethink its supply chains and the structure of its pharmaceutical industry, according to industry executives and consultants.
During a panel discussion at Biocom California's Global Life Sciences Partnering Conference, business development executives at various pharmaceutical companies advised biotech companies on everything from funding to manufacturing to deal structure.
With several more emergency use authorizations (EUAs) across the globe, COVID-19 efforts to flatten the emerging variants with cocktail therapies and tweaked vaccines are frantically underway. BioWorld has tracked 884 therapeutics and vaccines that have entered development for the deadly SARS-CoV-2 virus since it first emerged more than a year ago, and the U.S. government has now provided EUAs to three vaccines and six therapies.
Without any mega-mergers completed in the first two months of 2021, M&A values have significantly plummeted from those recorded in each of the last two years, although both deals and M&As in January and February are tracking similarly to prior years in terms of volume.
RSS
